IONS
Ionis Pharmaceuticals, Inc.
NasdaqGSUSDEQUITY
Healthcare
DELAYED
Sell
-46/100
Last price
43.30
▼ 0.20 (0.46%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
44.93
Prev close
43.50
Day high
44.67
Day low
43.18
Volume
2.19M
Market cap
$7.31B
P/E (TTM)
—
52W range
42.63 – 86.74
Day trading desk
Gap from prior close
+3.29%
Prior close 43.50
VWAP
43.96
-1.50% from price
Relative volume
0.97×
Normal
Session range
12.33%
40.00 – 44.93
Position in range
67%
Mid range
ATR (14D)
1.83
4.22% of price
Prior day high
43.96
PDH
Prior day low
42.63
PDL
Bid / ask spread
—
Quote not published
Session volume
3.65M
Avg 3.77M
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-4.12%
-6.1%
1M
-24.26%
-25.4%
3M
-47.90%
-52.4%
6M
-40.45%
-58.6%
YTD
-44.38%
-58.6%
1Y
-36.37%
-52.8%
3Y
-3.00%
-85.3%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on IONS open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
+2.69K
Net buying
Buy transactions
17
363.06K shares
Sell transactions
20
360.37K shares
Net transactions
+37
Buys less sells
Sell : buy shares
1.0 : 1
Mixed
Insider-held shares
1.01M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Jul 31, 26 | HAYDEN MICHAEL REUBEN Director |
BUY | 20.00K | $1.06M | Indirect |
| Jul 15, 26 | BERTHELSEN SPENCER R Director |
— | 5.22K | — | Direct |
| Jul 15, 26 | HERMAN JOAN E Director |
— | 5.22K | — | Direct |
| Jul 7, 26 | KORDASIEWICZ HOLLY B Officer |
SELL | 362 | $30.52K | Direct |
| Jul 7, 26 | DIAZ ALLENE M. Director |
SELL | 10.11K | $863.64K | Direct |
| Jul 7, 26 | DIAZ ALLENE M. Director |
CONVERSION | 10.11K | $476.33K | Direct |
| Jul 7, 26 | BENNETT C FRANK Officer |
SELL | 20.54K | $1.74M | |
| Jul 1, 26 | KLEIN JOSEPH S III Director |
SELL | 11.52K | $910.42K | Direct |
| Jul 1, 26 | KLEIN JOSEPH S III Director |
CONVERSION | 11.52K | $460.03K | Direct |
| Jun 26, 26 | BAROLDI JOSEPH Officer |
SELL | 5.63K | $451.70K | Indirect |
| Jun 26, 26 | BAROLDI JOSEPH Officer |
CONVERSION | 5.63K | $277.18K | Indirect |
| Jun 26, 26 | SCHNEIDER EUGENE Officer |
SELL | 26.00K | $2.11M | Direct |
| Jun 26, 26 | SCHNEIDER EUGENE Officer |
CONVERSION | 26.00K | $1.58M | Direct |
| Jun 26, 26 | O'NEIL PATRICK R General Counsel |
SELL | 3.07K | $245.52K | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
BAROLDI JOSEPH |
Officer | — | Sale |
BENNETT C FRANK |
Officer | — | Sale |
BERTHELSEN SPENCER R |
Director | 161.30K | Conversion of Exercise of derivative security |
BIRCHLER BRIAN |
Officer | 67.50K | Sale |
GEARY RICHARD S |
Officer | 59.66K | Sale |
HAYDEN MICHAEL REUBEN |
Director | — | Purchase |
HOUGEN ELIZABETH L |
Chief Financial Officer | 82.66K | Sale |
MONIA BRETT P |
Chief Executive Officer | 245.57K | Sale |
O'NEIL PATRICK R |
General Counsel | 61.47K | Sale |
SCHNEIDER EUGENE |
Officer | 77.11K | Sale |
Fundamentals
Market cap$7.31B
Enterprise value$7.40B
Revenue (TTM)$874.09M
Gross profit$-60.60M
EBITDA$-579.48M
Net income$-565.17M
EPS (TTM)$-3.52
Free cash flow$-346.76M
Total cash$2.10B
Total debt$2.19B
Book value / share$2.66
Shares outstanding166.18M
Float164.82M
Short % of float16.65%
Dividend yield0.00%
Beta (5Y)0.38
Valuation & profitability ratios
Trailing P/E—
Forward P/E-39.56
PEG ratio27.33
Price / sales—
Price / book16.57
EV / revenue8.47
EV / EBITDA-12.77
Gross margin-6.93%
Operating margin-38.18%
Profit margin-64.66%
Return on equity-105.50%
Return on assets-12.43%
Debt / equity497.80
Current ratio7.89
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $943.71M | $705.14M | $787.65M | $587.37M | +33.8% |
| Operating revenue | $943.71M | $705.14M | $787.65M | $587.37M | +33.8% |
| Cost of revenue | $15.91M | $11.21M | $9.13M | $14.12M | +41.9% |
| Gross profit | $927.80M | $693.92M | $778.51M | $573.25M | +33.7% |
| Research & development | $915.62M | $901.53M | $899.63M | $833.15M | +1.6% |
| Selling, general & admin | $393.90M | $267.50M | $232.62M | $150.29M | +47.3% |
| Total operating expense | $1.31B | $1.17B | $1.13B | $983.44M | +12.0% |
| Operating income | -$381.72M | -$475.11M | -$353.73M | -$410.19M | +19.7% |
| Net interest income | -$90.58M | -$90.46M | -$81.46M | -$8.12M | -0.1% |
| Pre-tax income | -$379.60M | -$460.07M | -$333.96M | -$257.99M | +17.5% |
| Tax provision | $1.79M | -$6.17M | $32.32M | $11.74M | +128.9% |
| Net income | -$381.39M | -$453.90M | -$366.29M | -$269.72M | +16.0% |
| Net income to common | -$381.39M | -$453.90M | -$366.29M | -$269.72M | +16.0% |
| Basic EPS | -2.38 | -3.04 | -2.56 | -1.90 | +21.7% |
| Diluted EPS | -2.38 | -3.04 | -2.56 | -1.90 | +21.7% |
| EBIT | -$295.32M | -$375.71M | -$252.51M | -$249.86M | +21.4% |
| EBITDA | -$272.63M | -$353.72M | -$230.01M | -$227.76M | +22.9% |
| Basic shares | 160.01M | 149.51M | 143.19M | 141.85M | +7.0% |
| Diluted shares | 160.01M | 149.51M | 143.19M | 141.85M | +7.0% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $372.26M | $242.08M | $399.27M | $276.47M | — | +53.8% |
| Cash & short-term investments | $2.68B | $2.30B | $2.33B | $1.99B | — | +16.5% |
| Inventory | $10.05M | $12.51M | $7.44M | $22.03M | — | -19.7% |
| Total current assets | $2.99B | $2.62B | $2.64B | $2.20B | — | +14.1% |
| Property, plant & equipment | $361.60M | $256.11M | $242.94M | $255.84M | — | +41.2% |
| Goodwill & intangibles | — | — | — | — | $29.00M | — |
| Total assets | $3.52B | $3.00B | $2.99B | $2.53B | — | +17.3% |
| Total current liabilities | $781.57M | $309.32M | $448.09M | $311.56M | — | +152.7% |
| Current debt | $454.69M | $9.28M | $53.16M | $7.54M | — | +4,800.2% |
| Long-term debt | $1.35B | $1.25B | $1.23B | $1.18B | — | +8.2% |
| Total debt | $2.06B | $1.42B | $1.45B | $1.37B | — | +45.7% |
| Total liabilities | $3.03B | $2.42B | $2.60B | $1.96B | — | +25.6% |
| Retained earnings | -$2.63B | -$2.25B | -$1.80B | -$1.43B | — | -17.0% |
| Shareholder equity | $489.09M | $588.35M | $386.69M | $572.89M | — | -16.9% |
| Working capital | $2.21B | $2.31B | $2.19B | $1.89B | — | -4.4% |
| Net tangible assets | $489.09M | $588.35M | $386.69M | $572.89M | — | -16.9% |
| Shares issued | 163.30M | 157.91M | 144.34M | 142.06M | — | +3.4% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$381.39M | -$453.90M | -$366.29M | -$269.72M | — | +16.0% |
| Depreciation & amortisation | $22.69M | $21.99M | $22.50M | $22.11M | — | +3.2% |
| Stock-based compensation | $133.87M | $130.20M | $105.81M | $100.26M | — | +2.8% |
| Change in working capital | -$51.22M | -$209.39M | -$77.26M | $7.57M | — | +75.5% |
| Operating cash flow | -$268.58M | -$500.95M | -$307.51M | -$274.37M | — | +46.4% |
| Capital expenditure | -$57.08M | -$50.34M | -$27.99M | -$20.10M | — | -13.4% |
| Investing cash flow | -$277.78M | -$134.03M | -$214.13M | -$262.64M | — | -107.3% |
| Share buybacks | — | — | — | $0 | $0 | — |
| Financing cash flow | $675.84M | $478.06M | $644.08M | -$55.30M | — | +41.4% |
| Free cash flow | -$325.67M | -$551.29M | -$335.50M | -$294.47M | — | +40.9% |
| End cash position | $372.26M | $242.08M | $399.27M | $276.47M | — | +53.8% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $267.95M | $246.09M | $203.33M | $156.72M | $452.05M | +8.9% |
| Operating revenue | $267.95M | $246.09M | $203.33M | $156.72M | $452.05M | +8.9% |
| Cost of revenue | $2.74M | $3.00M | $7.96M | $2.34M | $4.15M | -8.7% |
| Gross profit | $265.21M | $243.09M | $195.37M | $154.38M | $447.90M | +9.1% |
| Research & development | $217.11M | $210.17M | $279.65M | $217.75M | $217.46M | +3.3% |
| Selling, general & admin | $150.40M | $150.40M | $130.20M | $96.80M | $90.60M | 0.0% |
| Total operating expense | $367.51M | $360.57M | $409.85M | $314.55M | $308.06M | +1.9% |
| Operating income | -$102.30M | -$117.48M | -$214.47M | -$160.17M | $139.84M | +12.9% |
| Net interest income | -$22.11M | -$22.54M | -$22.76M | -$22.15M | -$22.75M | +1.9% |
| Pre-tax income | -$113.38M | -$92.31M | -$227.92M | -$128.39M | $123.53M | -22.8% |
| Tax provision | $1.26M | $218.00K | $1.48M | $213.00K | -$20.00K | +479.8% |
| Net income | -$114.65M | -$92.53M | -$229.39M | -$128.61M | $123.55M | -23.9% |
| Net income to common | -$114.65M | -$92.53M | -$229.39M | -$128.61M | $123.55M | -23.9% |
| Basic EPS | -0.69 | -0.56 | -1.41 | -0.80 | 0.78 | -23.2% |
| Diluted EPS | -0.69 | -0.56 | -1.41 | -0.80 | 0.70 | -23.2% |
| EBIT | -$92.88M | -$71.97M | -$206.86M | -$107.84M | $144.78M | -29.0% |
| EBITDA | -$85.24M | -$64.53M | -$199.51M | -$103.34M | $150.23M | -32.1% |
| Basic shares | 165.42M | 164.87M | 162.00M | 159.76M | 159.14M | +0.3% |
| Diluted shares | 165.42M | 164.87M | 162.00M | 159.76M | 182.33M | +0.3% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $350.06M | $173.38M | $372.26M | $338.34M | $297.30M | +101.9% |
| Cash & short-term investments | $2.05B | $1.92B | $2.68B | $2.24B | $2.29B | +7.1% |
| Inventory | $50.83M | $5.56M | $10.05M | $10.47M | $8.48M | +814.8% |
| Total current assets | $2.49B | $2.94B | $2.99B | $2.52B | $2.58B | -15.2% |
| Property, plant & equipment | $386.69M | $377.46M | $361.60M | $348.11M | $275.88M | +2.4% |
| Total assets | $2.99B | $3.45B | $3.52B | $3.03B | $2.99B | -13.2% |
| Total current liabilities | $315.64M | $716.59M | $781.57M | $903.46M | $897.24M | -56.0% |
| Current debt | — | $432.50M | $454.69M | $630.91M | $630.12M | — |
| Long-term debt | $1.35B | $1.35B | $1.35B | $595.91M | $625.49M | +0.1% |
| Total debt | $1.61B | $2.04B | $2.06B | $1.49B | $1.42B | -20.9% |
| Total liabilities | $2.55B | $2.96B | $3.03B | $2.42B | $2.35B | -13.6% |
| Retained earnings | -$2.84B | -$2.72B | -$2.63B | -$2.40B | -$2.27B | -4.2% |
| Shareholder equity | $439.74M | $491.41M | $489.09M | $617.97M | $631.72M | -10.5% |
| Working capital | $2.18B | $2.22B | $2.21B | $1.62B | $1.68B | -2.0% |
| Net tangible assets | $439.74M | $491.41M | $489.09M | $617.97M | $631.72M | -10.5% |
| Shares issued | 165.90M | 165.90M | 163.30M | 161.14M | 159.20M | 0.0% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$114.65M | -$92.53M | -$229.39M | -$128.61M | $123.55M | -23.9% |
| Depreciation & amortisation | $7.64M | $7.45M | $7.34M | $4.50M | $5.45M | +2.6% |
| Stock-based compensation | $45.59M | $43.27M | $43.32M | $31.15M | $29.69M | +5.4% |
| Change in working capital | $611.21M | -$730.12M | $23.86M | -$5.41M | -$28.48M | +183.7% |
| Operating cash flow | $565.53M | -$792.82M | -$137.71M | -$131.44M | $151.34M | +171.3% |
| Capital expenditure | -$18.23M | -$23.25M | -$22.66M | -$6.93M | -$14.27M | +21.6% |
| Investing cash flow | $23.50M | $536.82M | -$419.50M | $91.34M | -$120.07M | -95.6% |
| Financing cash flow | -$412.29M | $57.26M | $591.18M | $81.22M | $1.25M | -820.1% |
| Free cash flow | $547.30M | -$816.07M | -$160.37M | -$138.37M | $137.07M | +167.1% |
| End cash position | $350.06M | $173.38M | $372.26M | $338.34M | $297.30M | +101.9% |
Options analytics
Put / call volume
7.28
Put-heavy session
Put / call open interest
4.57
Positioning, not flow
Max pain
80.00
+81.8% from spot
ATM implied vol
3.1%
Nearest strike to spot
Skew (10% OTM)
0.0%
Calls bid over puts
Call volume
426
Contracts, this expiry
Put volume
3.10K
Contracts, this expiry
Heaviest call OI
87.50
34 contracts
Heaviest put OI
80.00
200 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.88 | -0.42 | +51.7% |
| Mar 2026 | -0.78 | -0.30 | +60.9% |
| Dec 2025 | -1.22 | -1.15 | +5.6% |
| Sep 2025 | -1.05 | -0.61 | +41.8% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.92 | 8 | $185.50M | +18.2% |
| Next quarter | -0.89 | 8 | $240.74M | +18.6% |
| Current year | -2.70 | 10 | $919.55M | -2.6% |
| Next year | -1.11 | 10 | $1.36B | +48.4% |
Analyst targets & ownership
Mean target$83.64
High target$105.00
Low target$54.00
Implied upside93.16%
Analyst count22
ConsensusBUY
Strong buy / Buy9 / 9
Hold5
Sell / Strong sell0 / 0
Held by insiders0.61%
Held by institutions110.37%
Institutions holding719
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
44.34
-2.34% from price
SMA 20
46.73
-5.85% from price
SMA 50
53.41
-17.61% from price
SMA 100
62.25
-30.44% from price
SMA 200
70.05
-37.19% from price
EMA 12
45.23
-4.26% from price
EMA 26
48.55
-10.81% from price
EMA 50
53.01
-18.32% from price
RSI (14)
32.7
Neutral
MACD (12,26,9)
-3.32
Hist 0.17
ATR (14)
1.83
4.15% of price
Realised vol 30D
44.6%
Annualised
Bollinger upper
54.74
20, 2σ
Bollinger lower
38.72
20, 2σ
50 / 200 cross
Death
53.41 vs 70.05
Trend bias
Below 200
-37.19%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.45
Less volatile than market
Correlation to SPY
0.14
Largely independent
Realised vol 30D
44.6%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-49.7%
Peak to trough
Max drawdown 5Y
-52.4%
Peak to trough
ATR 14
1.83
4.15% of price
Beta (reported)
0.38
5Y monthly, from filing
Short interest
Shares short
20.89M
Prior 20.91M
Change vs prior
-0.1%
Shorts covering
% of float
16.65%
Elevated
% of shares out
12.57%
Against total outstanding
Days to cover
6.6
Crowded exit
Float
164.82M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 24, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Sep 22, 26 | JP Morgan | MAINTAINED | Overweight | Overweight |
| Sep 15, 26 | Guggenheim | MAINTAINED | Buy | Buy |
| Sep 9, 26 | Barclays | MAINTAINED | Overweight | Overweight |
| Sep 8, 26 | Morgan Stanley | MAINTAINED | Overweight | Overweight |
| Sep 8, 26 | Goldman Sachs | MAINTAINED | Neutral | Neutral |
| Sep 8, 26 | BMO Capital | MAINTAINED | Market Perform | Market Perform |
| Sep 8, 26 | Canaccord Genuity | MAINTAINED | Buy | Buy |
| Sep 8, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Sep 4, 26 | Needham | MAINTAINED | Buy | Buy |
| Sep 4, 26 | BMO Capital | MAINTAINED | Market Perform | Market Perform |
| Sep 4, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio0.00%
Ex-dividend date—
Next pay date—
Last split—
Split date—
SEC filings
Corporate Changes & Voting Matters
8-K · 2026-09-23
Corporate Changes & Voting Matters
8-K · 2026-09-04
Offering Registrations
S-8 · 2026-07-31
Periodic Financial Reports
10-Q · 2026-07-29
Corporate Changes & Voting Matters
8-K · 2026-07-10
Corporate Changes & Voting Matters
8-K · 2026-07-09
Corporate Changes & Voting Matters
8-K · 2026-06-24
Corporate Changes & Voting Matters
8-K · 2026-06-12
Headlines
Novartis Strengthens RNA Therapeutics Pipeline With $7.8B Abogen Deal
Zacks · 2d ago
Cathie Wood Makes $64 Million Bet on Two Stocks
GuruFocus.com · 8d ago
4 RNA Therapeutics Stocks Leading the Next Wave of Innovation
Zacks · 9d ago
Ionis Pharmaceuticals (IONS) Stock Looks Pricey On Its 45% YTD Slide
Simply Wall St. · 12d ago
Failure of Novartis’ Pelacarsen Could Reshape the Lp(a) Race for CRISPR and Ionis
Insider Monkey · 13d ago
The Biggest Losers In Biotech — And It Had Nothing To Do With 'Compelling,' 'Best-In-Disease' Data
Investor's Business Daily · 13d ago
Roche, Ionis RNA drug scores in kidney disease study
BioPharma Dive · 14d ago
Ionis Delivers Positive Late-Stage Results for Two Partnered Drugs
Zacks · 14d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.